Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 2/20 | 0.32 |
| ▸ | EDNRA | P25101 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261114 | 0.89 | EDNRB (0.33) | EDNRBEDNRA | |
| SCHEMBL5259046 | 0.76 | EDNRB (0.36) | EDNRBEDNRA | |
| SCHEMBL4145065 | 0.76 | NR1D1 (0.33) | L3MBTL1MEN1KMT2A | |
| SCHEMBL5313941 | 0.74 | EDNRB (0.34) | EDNRBEDNRA | |
| SCHEMBL4149087 | 0.73 | PTPN2 (0.30) | — | |
| SCHEMBL4694873 | 0.68 | NR1D1 (0.34) | — | |
| SCHEMBL24326337 | 0.65 | REN (0.37) | L3MBTL1MEN1KMT2A | |
| SCHEMBL4693024 | 0.65 | — | — | |
| SCHEMBL5185704 | 0.63 | KMT2A (0.43) | L3MBTL1MEN1KMT2A | |
| SCHEMBL5252254 | 0.63 | KDM4E (0.39) | EDNRBEDNRAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | EDNRB 4225/4885EDNRA 4435/4885L3MBTL1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.